Healthcare · NSE: CONCORDBIO
Concord Biotech
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 28 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹12,156Cr
- P/E
- 43.0×
- 1Y return
- −22.49%
- From 52W high
- −28.1%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 309 | 247 | +25.1% | 257 | +20.0% |
| EBITDA | 104 | 88 | +18.0% | 82 | +26.7% |
| EBITDA margin | 33.8% | 35.8% | -205 bps | 32.0% | +178 bps |
| PBTProfit before tax | 96 | 83 | +15.3% | 77 | +24.7% |
| Net profit | 71 | 64 | +11.1% | 59 | +20.7% |
| EPS (₹) | 6.65 | 6.03 | +10.3% | 5.52 | +20.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
More figures from the call
“this year also we are saying that we should be growing slightly better off than the 18-19% because some of the challenges which were there led to somewhat of”
“how fast the ramp-up can happen on both of these two units and once that does take place, we should be moving from the 33-34% to 38-39%”
“So for the capacity, I would say that 21% was the capacity utilization for Unit-II and around 5% is for the injectable unit, Unit-IV”
“So, Alankar, the utilization for Unit I stood at 75% and Unit III at 55%.”
“So, we already have around 30 plus products, we have another 10 to 15 in the pipeline and significant capacities have been built to cater to the requirements for these products once they become commercial.”
In short
- 01Q2 FY27 revenue was Rs 309.1 crore, up 25%; H1 revenue rose 26%.
- 02FY27 revenue growth expected slightly above the historical 18%.
- 03EBITDA margin expected at 38% to 40% over the next few years, from 33.8% in Q2.
- 04Gross margin fell about 400 bps in Q2, mainly on raw material (solvent) prices.
- 05Capex of about Rs 50-60 crore a year expected for this year and next.
- 06Injectables contracts expected in H2; about Rs 300 crore injectables revenue built in over 3 to 4 years.
- 07Utilisation: Unit I 75%, Unit III 55%, Unit II 21%, injectables Unit IV 5%.
- 08Zero debt, with about Rs 445 crore cash; 1:1 bonus issue approved.
Capacity
Formulation: Formulation facility utilisation expected to rise with Stellon and new ANDA approvals
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 9
Formulation: Formulation facility utilisation expected to rise with Stellon and new ANDA approvals
“And in addition to that, with Stellon coming in, and with new ANDA approvals coming in, we expect that facility utilization would also increase.”
Segments
API: Q2 API revenue Rs 250.1 crore, up 30%; formulation Rs 58.9 crore, up 6%
Raviraj Karia · Chief Financial Officer · p. 6
API: Q2 API revenue Rs 250.1 crore, up 30%; formulation Rs 58.9 crore, up 6%
“API revenue for the quarter stood at Rs. 250.1 crore, registering a growth of 30% year-on-year, while formulation revenue stood at 58.9 crores, growing by 6%.”
Formulation: Formulation growth held back by customers buying API instead, and shift to Stellon
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
Formulation: Formulation growth held back by customers buying API instead, and shift to Stellon
“The relatively modest growth in overall formulation revenue was primarily attributable to a shift in the procurement strategies across emerging markets, with certain customers increasingly opting to procure API instead of finished formulations, as well as the transition of business from Advergent to our wholly owned subsidiary in the US, Stellon Biotech.”
Domestic formulation: Domestic formulation business grew 29% in Q2
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
Domestic formulation: Domestic formulation business grew 29% in Q2
“The domestic formulation business delivered a strong growth of 29% in Q2.”
Domestic API: Q2 domestic API revenue up 42%; export revenue up 8%
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 5
Domestic API: Q2 domestic API revenue up 42%; export revenue up 8%
“Domestic API revenue grew by 42% year-on-year in Q2 FY ‘27, while export revenue increased by 8%.”
Oncology: Oncology business nearly doubled year-on-year
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 3
Oncology: Oncology business nearly doubled year-on-year
“Our oncology business nearly doubled compared to the corresponding period last year.”
Demand
Anti-infectives: Several US customers qualified Concord for Nystatin; commercial supplies yet to begin
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 7
Anti-infectives: Several US customers qualified Concord for Nystatin; commercial supplies yet to begin
“We also have several U.S. customers who have qualified Concord as their source. So we have provided them validation quantities. Commercial supplies are yet to begin.”
Oncology: Romidepsin picked up as customers launched in the US; Everolimus sees traction
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 8
Oncology: Romidepsin picked up as customers launched in the US; Everolimus sees traction
“When it comes to oncology products like Romidepsin has picked up well because of some of the customers launching the products in the U.S. market and products like Everolimus continue to see traction.”
Inspira: India market for Concord's dermatology range close to Rs 5,000 crore
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 11
Inspira: India market for Concord's dermatology range close to Rs 5,000 crore
“the India-based market itself is for the Concord range of products is close to around Rs. 5,000 crores and here again, we are the only company in India which is fully integrated right from API to finished.”
Immunosuppressants: Immunosuppressant market grows about 10%; second-source wins a bigger driver
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 17
Immunosuppressants: Immunosuppressant market grows about 10%; second-source wins a bigger driver
“So, I would say immunosuppressants will continue to grow, and for that, the growth not only comes from the market growth, which is around 10%, but also from us gaining the second source, which actually is a much bigger contributor to the growth of the immunosuppressants business.”
Immunosuppressants: Latin America opening up after ANVISA inspections
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 17
Immunosuppressants: Latin America opening up after ANVISA inspections
“Certain markets like Latin America is opening up for us because of the ANVISA inspections that has happened.”
Margins and costs
Gross margin fell about 400 bps, mainly on higher raw material and solvent prices
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 5
Gross margin fell about 400 bps, mainly on higher raw material and solvent prices
“Speaking about margins for the current year, we witnessed a gross margin contraction of approximately 400 basis points year-on-year, primarily driven by an increase in raw material prices, particularly the solvents, amidst ongoing geopolitical uncertainties and broader supply chain disruptions.”
Company expects to recover the margin impact on a full-year basis
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 5
Company expects to recover the margin impact on a full-year basis
“However, on a full-year basis, we expect to recover the margin impact to an improvement in revenue coupled with effective cost optimization measures and optimum inventory management.”
Higher power and fuel cost hit margins, partly offset by renewable energy
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 5
Higher power and fuel cost hit margins, partly offset by renewable energy
“Margins were also impacted by higher power and fuel cost. This was partly offset by the renewable energy sources in which we invested last year.”
Q2 FY27 EBITDA margin at 33.8%
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 5
Q2 FY27 EBITDA margin at 33.8%
“On the EBITDA front, our reported margins stood at 33.8% in Q2 FY ‘27.”
H1 EBITDA margin 33.0% versus 33.2% a year earlier
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 5
H1 EBITDA margin 33.0% versus 33.2% a year earlier
“For H1 FY ‘27, EBITDA margins remained fairly stable at 33.0% compared to 33.2% in H1 FY ‘26, despite the contraction in gross margins.”
Debt and working capital
Zero debt; cash and equivalents about Rs 445 crore at 30 September 2026
Raviraj Karia · Chief Financial Officer · p. 7
Zero debt; cash and equivalents about Rs 445 crore at 30 September 2026
“Lastly, Concord continues to maintain a zero-debt balance sheet with cash and cash equivalents of around Rs. 445 crores as of September 30, 2026, reflecting our continued focus on financial discipline and balance sheet strength.”
Acquisitions and new business
Formulation: ANDA approvals received for Tofacitinib and Mycophenolate Mofetil Oral Suspension
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
Formulation: ANDA approvals received for Tofacitinib and Mycophenolate Mofetil Oral Suspension
“We received ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension which strengthen our formulation portfolio.”
API: Drug Master File filed for Fidaxomicin in the US
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
API: Drug Master File filed for Fidaxomicin in the US
“We also filed a Drug Master File for Fidaxomicin in the US, which adds to our API opportunities in that market.”
Inspira: Inspira dermatology division launched
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
Inspira: Inspira dermatology division launched
“We have launched Inspira, our dermatology division. It takes us beyond our existing portfolio into science-led skin health solutions.”
Anti-infectives: Fusidic acid to be commercialised in emerging markets, then global markets
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 8
Anti-infectives: Fusidic acid to be commercialised in emerging markets, then global markets
“So that is a product that in the next coming few months to quarter, we would be commercializing in emerging markets and then extending it to global markets.”
Inspira: Inspira to focus on eczema, anti-infective, antifungal and acne products
Ankur Vaid · Joint Managing Director & Chief Executive Officer · Q&A · p. 11
Inspira: Inspira to focus on eczema, anti-infective, antifungal and acne products
“And within the dermatology, the key segments that we would be working is towards eczema, where we have products like Tacrolimus, Pimecrolimus, anti-infectives, antifungal”
Dividends and buybacks
1:1 bonus issue approved by shareholders, to take effect in coming weeks
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
1:1 bonus issue approved by shareholders, to take effect in coming weeks
“Lastly, board recommendation of 1:1 bonus issue has been approved by shareholders and will take effect in the coming weeks.”
Other
Q2 FY27 revenue Rs 309.1 crore, up 25% year-on-year
Raviraj Karia · Chief Financial Officer · p. 6
Q2 FY27 revenue Rs 309.1 crore, up 25% year-on-year
“Revenue for Q2 FY ‘27 stood at Rs. 309.1 crore compared to Rs. 247.1 crore in Q2 FY ‘26, registering a year-on-year growth of 25%.”
H1 FY27 revenue up 26% to Rs 566.6 crore
Raviraj Karia · Chief Financial Officer · p. 6
H1 FY27 revenue up 26% to Rs 566.6 crore
“For HY ‘27, revenue increased by 26% to Rs. 566.6 crores compared to Rs. 451.1 crore in the same period HY FY ‘26.”
USFDA inspection of Unit-II completed; ANVISA approval for Unit-III
Ankur Vaid · Joint Managing Director & Chief Executive Officer · p. 4
USFDA inspection of Unit-II completed; ANVISA approval for Unit-III
“We successfully completed the USFDA inspection of our Unit-II formulation facility at Valthera, Ahmedabad. We also received ANVISA approval for our Unit-III facility at Limbasi.”
Q2 EBITDA Rs 104.4 crore, up about 18%; H1 EBITDA up 25% to Rs 187 crore
Raviraj Karia · Chief Financial Officer · p. 7
Q2 EBITDA Rs 104.4 crore, up about 18%; H1 EBITDA up 25% to Rs 187 crore
“EBITDA for Quarter 2 FY ‘27 stood at Rs. 104.4 crores, registering a year-on-year growth of around 18%. For HY FY ‘27, EBITDA increased by 25% to Rs. 187 crores.”
Q2 PAT Rs 69.6 crore, up 10.3%; H1 PAT up 19% to Rs 127.3 crore
Raviraj Karia · Chief Financial Officer · p. 7
Q2 PAT Rs 69.6 crore, up 10.3%; H1 PAT up 19% to Rs 127.3 crore
“When I talk about the PAT for Q2 FY ‘27, it stood at Rs. 69.6 crores, registering a year-on-year growth of 10.3%. For H1 FY ‘27, PAT increased by 19% to Rs. 127.3 crore.”
Sources
- Earnings call transcript, Q2 FY27 Filed 3 Nov 2026 · 18 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

